MTOR and cancer: CNI-free immunosuppression after LTx based on mTOR inhibitors were presented as a conference abstract and included 12 long term patients (three with malignancy) converted to a CNI-free everolimus-based immunosuppressive regimen mainly to preserve kidney function [17].